Copyright © Inderes 2011 - present. All rights reserved.

Aiforia Technologies

1.87 EUR

-1.32 %

2,146 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

-1.32 %
-20.76 %
-24.90 %
-29.17 %
-44.35 %
-48.06 %
-55.48 %
-
-63.04 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
63M EUR
Turnover
53.33K EUR
P/E (adj.) (25e)
-4.84
EV/EBIT (adj.) (25e)
-5.5
P/B (25e)
4.78
EV/S (25e)
18.06
Dividend yield-% (25e)
-
Coverage
Recommendation
Accumulate
Target price
3.20 EUR
Updated
2025-11-19
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 2025-11-19

Latest extensive report

Released: 2025-04-24

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6/3
2026

Annual report '25

2/4
2026

General meeting '26

28/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Greetings to the thread, Regarding company coverage, we have some news: we are transferring the primary coverage responsibility for Aiforia mainly to me. Antti L will continue to work with Aiforia as a supporting analyst. I am probably more or less familiar to most readers, but for...
yesterday
by Antti Siltanen
51
Without taking a position on the analysis itself, Nuways has a “buy” recommendation for almost every client, “under review” for a few, and a few unfortunate ones have been assigned a “hold”. In Germany, these views are consistently very positive. nuways-ag.com Companies Our research...
2/11/2026, 6:24 PM
by Verneri Pulkkinen
30
I now have a full, good-sized position in Aiforia. At least I interpret this latest -15% as a completely extra “Faron discount.” The stock was already at my buy price even before this. It seems quite promising to me. Many contracts have already been signed, and there’s no reason ...
2/12/2026, 3:24 PM
by JusaVaan
23
Answering my own question: The volume at Fimlab was approx. 1,600 slides in September 2025 and 3,500 in October, and the number is growing. Price per slide taken from the comprehensive report And with a good margin Fimlab is, however, on the smaller end of the won tenders, so you...
2/12/2026, 7:53 AM
by Jekkku
22
Quoting the message rather than responding to it. Now that Aiforia has taken a real beating on the stock market and the valuation has dropped to 66 million, I hope it won’t be bought out on the cheap now. $81m was paid for Paige, and it is clearly behind Aiforia, at least in terms...
2/12/2026, 11:38 AM
by Jekkku
21
Pre-results update. Despite the share price, target €3.80 & Buy Summary: We remain upbeat on Aiforia’s Foundation Engine and its clinical and commercial scalability. Aiforia’s clinical footprint now covers breast, prostate, and lung cancers, strengthened by its new gastric cancer...
2/11/2026, 4:54 PM
by Opa
16
Well, welcome back to a semi-familiar environment then. I tried to pass a question to Luiro for Jukka’s interview regarding Aiforia’s newest model, i.e., gastric cancer: how they see its volumes and whether they have discussed with pathologists and gastroscopists (i.e., surgeons ...
yesterday
by Vino Pino
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.